zlacker

[parent] [thread] 0 comments
1. caeril+(OP)[view] [source] 2023-08-04 13:02:52
His history is "fine", if you consider that this is par for the course for the pharma industry. Acquiring IP rights to a drug, then ratcheting the price is a tale as old as time.

Shkreli's main sin is choosing a drug that is primarily used by a specific protected class. It treats parasitic infections that normally don't take hold in people with healthy immune response. Daraprim's customer list is something like 92% AIDS patients, and 8% immuno-compromised for other reasons.

Shkreli did something that happens all the time, and we don't bat an eye. But you don't do it to protected classes without a mob response.

[go to top]